Top

Published in:

01-06-2019 | Research Article

Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [¹⁸F]DCFPyL PET/CT

Authors: Yafu Yin, Scott P. Campbell, Mark C. Markowski, Philip M. Pierorazio, Martin G. Pomper, Mohamad E. Allaf, Steven P. Rowe, Michael A. Gorin

Published in: Molecular Imaging and Biology | Issue 3/2019

Abstract

Purpose

To investigate the utility of prostate-specific membrane antigen (PSMA)-targeted [¹⁸F]DCFPyL positron emission tomography (PET)/X-ray computed tomography (CT) imaging for the detection of sites of disease in patients with metastatic non-clear cell renal cell carcinoma (RCC).

Procedures

Eight patients with metastatic non-clear cell RCC underwent imaging with PSMA-targeted [¹⁸F]DCFPyL PET/CT. Imaged RCC histologic subtypes included papillary RCC (n = 3), chromophobe RCC (n = 2), unclassified RCC (n = 2), and Xp11 translocation RCC (n = 1). Using comparison to conventional CT and/or magnetic resonance imaging as reference, two radiologists with expertise in nuclear medicine identified putative sites of disease on [¹⁸F]DCFPyL PET/CT and classified each lesion as having no radiotracer uptake, equivocal uptake, or definitive uptake.

Resuts

In total, 73 metastatic sites and 3 primary tumors compatible with sites of non-clear cell RCC were identified on conventional imaging. Metastatic sites of disease included lymph nodes (n = 40), venous thrombi (n = 3), pulmonary nodules (n = 10), bone lesions (n = 15), brain lesions (n = 3), and retroperitoneal masses (n = 2). Only 10 of the 73 lesions (13.7 %) were classified as having definitive radiotracer uptake (median SUV_max = 3.25, range = 1.2–9.5), 14 lesions (19.2 %) had equivocal uptake (median SUV_max = 2.85, range = 0.5–6.5), and 49 lesions (67.1 %) had no definitive uptake above background (median SUV_max = 1.7, range = 0.2–3.0). The three primary renal tumors demonstrated lower radiotracer avidity relative to surrounding normal renal parenchyma.

Conclusions

A small proportion of sites of non-clear cell RCC showed uptake of the PSMA-targeted radiotracer [¹⁸F]DCFPyL. Unlike for clear cell RCC, the results of this study indicate that PSMA-based PET is not appropriate for imaging other RCC subtypes.

Fitzmaurice C, Allen C, Barber RM et al (2017) Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3:524–548CrossRefPubMed

Frank I, Blute ML, Cheville JC et al (2003) Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170:2217–2220CrossRefPubMed

Tickoo SK, Gopalan A (2008) Pathologic features of renal cortical tumors. Urol Clin North Am 35:551–561CrossRefPubMed

Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, Clark PE, Davis BJ, Derweesh IH, Giambarresi L, Gervais DA, Hu SL, Lane BR, Leibovich BC, Pierorazio PM (2017) Renal mass and localized renal cancer: AUA guideline. J Urol 198:520–529CrossRefPubMed

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67:913–924CrossRefPubMed

Brufau BP, Cerqueda CS, Villalba LB, Izquierdo RS, González BM, Molina CN (2013) Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. Radiographics 33:1691–1716CrossRefPubMed

Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, Kao CH (2012) Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 12:464–474CrossRefPubMedPubMedCentral

Liu Y (2016) The place of FDG PET/CT in renal cell carcinoma: value and limitations. Front Oncol 6:201PubMedPubMedCentral

Caldarella C, Muoio B, Isgro MA et al (2014) The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiol Oncol 48:219–227CrossRefPubMedPubMedCentral

10.

Gorin MA, Rowe SP, Allaf ME (2015) Nuclear imaging of renal tumours: a step towards improved risk stratification. Nat Rev Urol 12:445–450CrossRefPubMed

11.

Khandani AH, Rathmell WK (2012) Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Semin Nucl Med 42:221–230CrossRefPubMed

12.

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85PubMed

13.

Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3:216–225CrossRefPubMed

14.

Salas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes LB, Kiess AP, Allaf ME, Pomper MG, Gorin MA, Rowe SP (2018) Imaging of non-prostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms. J Nucl Med 59:871–877CrossRefPubMed

15.

Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF (2015) First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging 42:1622–1623CrossRefPubMed

16.

Sasikumar A, Joy A, Nanabala R, Pillai MRA, Thomas B, Vikraman KR (2016) ⁶⁸Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 43:795–796CrossRefPubMed

17.

Sasikumar A, Joy A, Pillai MR et al (2017) Diagnostic value of ⁶⁸Ga PSMA-11 PET/CT imaging of brain tumors-preliminary analysis. Clin Nucl Med 42:e41–e48CrossRefPubMed

18.

Sasikumar A, Joy A, Pillai MRA, Alex TM, Narayanan G (2017) ⁶⁸Ga-PSMA PET/CT in osteosarcoma in fibrous dysplasia. Clin Nucl Med 42:446–447CrossRefPubMed

19.

Sasikumar A, Joy A, Pillai M, S B, SR S (2017) ⁶⁸Ga-PSMA uptake in an incidentally detected gastrointestinal stromal tumor in a case of suspected carcinoma prostate. Clin Nucl Med 42:e447–e448CrossRefPubMed

20.

Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart JR, Maes A, Ebenhan T, van de Wiele C (2017) ⁶⁸Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging 44:689–694CrossRefPubMed

21.

Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, Cho SY, Pomper MG, Allaf ME (2015) Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. Ann Nucl Med 29:877–882CrossRefPubMedPubMedCentral

22.

Rowe SP, Gorin MA, Hammers HJ, Pomper MG, Allaf ME, Javadi MS (2016) Detection of ¹⁸F-FDG PET/CT occult lesions with ¹⁸F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. Clin Nucl Med 41:83–85CrossRefPubMedPubMedCentral

23.

Chang SS, Reuter VE, Heston WD, Gaudin PB (2001) Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 57:801–805CrossRefPubMed

24.

Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, Gorin MA (2018) Low levels of PSMA expression limit the utility of ¹⁸F-DCFPyL PET/CT for imaging urothelial carcinoma. Ann Nucl Med 32:69–74CrossRefPubMed

25.

Rhee H, Blazak J, Tham CM, Ng KL, Shepherd B, Lawson M, Preston J, Vela I, Thomas P, Wood S (2016) Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res 6:76CrossRefPubMedPubMedCentral

26.

Sasikumar A, Joy A, Nanabala R, Unni M, TK P (2016) Complimentary pattern of uptake in ¹⁸F-FDG PET/CT and ⁶⁸Ga-prostate-specific membrane antigen PET/CT in a case of metastatic clear cell renal carcinoma. Clin Nucl Med 41:e517–e519CrossRefPubMed

27.

Rhee H, Ng KL, Tse BW et al (2016) Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology 48:613–616CrossRefPubMed

28.

Gorin MA, Rowe SP, Hooper JE, Kates M, Hammers HJ, Szabo Z, Pomper MG, Allaf ME (2017) PSMA-targeted ¹⁸F-DCFPyL PET/CT imaging of clear cell renal cell carcinoma: results from a rapid autopsy. Eur Urol 71:145–146CrossRefPubMed

29.

Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS (2017) Utility of ⁶⁸Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol 61:372–378CrossRefPubMed

30.

Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halaç M, Kanmaz B (2014) ⁶⁸Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 41:1461–1462CrossRefPubMed

31.

Sawicki LM, Buchbender C, Boos J, Giessing M, Ermert J, Antke C, Antoch G, Hautzel H (2017) Diagnostic potential of PET/CT using a ⁶⁸Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging 44:102–107CrossRefPubMed

32.

Baccala A, Sercia L, Li J, Heston W, Zhou M (2007) Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 70:385–390CrossRefPubMed

33.

Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, Rabien A, Feldmann G, Brossart P, Bundschuh RA, Ahmadzadehfar H, Essler M, Toma M, Müller SC, Ellinger J, Hauser S, Kristiansen G (2018) Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol 199:370–377CrossRefPubMed

34.

Ravert HT, Holt DP, Chen Y, Mease RC, Fan H, Pomper MG, Dannals RF (2016) An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [¹⁸F]DCFPyL. J Labelled Comp Radiopharm 59:439–450CrossRefPubMedPubMedCentral

35.

Gorin MA, Rowe SP (2017) Kidney cancer: PSMA: a potential therapeutic target in RCC. Nat Rev Urol 14:646–647CrossRefPubMed

Title: Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT
Authors: Yafu Yin
Scott P. Campbell
Mark C. Markowski
Philip M. Pierorazio
Martin G. Pomper
Mohamad E. Allaf
Steven P. Rowe
Michael A. Gorin
Publication date: 01-06-2019
Publisher: Springer International Publishing
Published in: Molecular Imaging and Biology / Issue 3/2019
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-018-1271-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [¹⁸F]DCFPyL PET/CT

Abstract

Purpose

Procedures

Resuts

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Resuts

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Commemorating Britton Chance

Physiological Whole-Brain Distribution of [18F]FDOPA Uptake Index in Relation to Age and Gender: Results from a Voxel-Based Semi-quantitative Analysis

Apoptotic PET Imaging of Rat Pulmonary Fibrosis with Small-Molecule Radiotracer

A Trimodal Imaging Platform for Tracking Viable Transplanted Pancreatic Islets In Vivo: F-19 MR, Fluorescence, and Bioluminescence Imaging

The Complexity and Fractal Geometry of Nuclear Medicine Images

[68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer